Astellas Pharma acquires Potenza Therapeutics in $404.7m deal

pharmanewsdaily- December 16, 2018 0

Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic ... Read More

Brooklyn Immuno Therapeutics acquires IRX Therapeutics’ assets for cytokine-based cancer therapy

pharmanewsdaily- November 19, 2018 0

Brooklyn Immuno Therapeutics, a New York-based clinical-stage biopharmaceutical company specializing in cytokine-based cancer therapies, has announced the acquisition of IRX Therapeutics' assets. The terms of ... Read More

Nordic Nanovector begins Phase 1b trial of Betalutin and Rituximab combo for follicular lymphoma

pharmanewsdaily- November 4, 2018 0

Nordic Nanovector has commenced the dosing of the first patient in its Phase 1b clinical trial, dubbed Archer-1, which aims to evaluate the combination of ... Read More

Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors

pharmanewsdaily- September 11, 2018 0

Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ... Read More

Roche set to fully acquire Flatiron Health in $1.9bn deal to accelerate cancer drug development

pallavi123- February 16, 2018 0

Roche, the Swiss pharmaceutical giant, has announced its plans to fully acquire Flatiron Health, a leading oncology software company, for $1.9 billion. This strategic move ... Read More

Lilly’s breast cancer drug abemaciclib shows promising results in phase 3 trial

pharmanewsdaily- March 22, 2017 0

Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination ... Read More

Genprex announces promising results for Oncoprex in Phase II lung cancer trial

pharmanewsdaily- January 7, 2017 0

Texas-based biopharmaceutical company Genprex has unveiled positive interim data from an ongoing phase II clinical trial, NCT01455389, for its lung cancer drug candidate, Oncoprex. Conducted ... Read More